Janney Capital resumes coverage on Cara Therapeutics (NASDAQ: CARA) with a Buy rating and a price target of $28.00.Analyst Ken ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE